- Molecular NameNiacin
- Synonym3-Pyridinecarboxylic acid; Acide Nicotinique; Acidum Nicotinicum; M-Pyridinecarboxylic Acid; NAH; niacin; Nicotine Acid; Nicotinic Acid; Pyridinecarboxylic Acid; Pyridylcarboxylic Acid; Vitamin B3
- Weight123.111
- Drugbank_IDDB00627
- ACS_NO59-67-6
- Show 3D model
- LogP (experiment)0.36
- LogP (predicted, AB/LogP v2.0)0.44
- pka4.75
- LogD (pH=7, predicted)-2.73
- Solubility (experiment)18 mg/ml
- LogS (predicted, ACD/Labs)(ph=7)0.91
- LogSw (predicted, AB/LogsW2.0)6.51
- Sw (mg/ml) (predicted, ACD/Labs)18.56
- No.of HBond Donors1
- No.of HBond Acceptors3
- No.of Rotatable Bonds1
- TPSA50.19
- StatusFDA approved
- AdministrationN/A
- PharmacologyNiacin and niacinamide are indicated for prevention and treatment of vitamin B3 deficiency states.
- Absorption_value94.0
- Absorption (description)Niacin is well-absorbed but undergoes first-pass metabolism. Absorption is improved when taken with a low-fat meal.
- Caco_2N/A
- BioavailabilityN/A
- Protein bindingN/A
- Volume of distribution (VD)N/A
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmNiacin (nicotinic acid) is metabolized to nicotinamide, which in turn is converted to the coenzyme NAD and other inactive metabolites. It also undergoes direct glycine conjugation to nicotinuric acid.
- Half life0.15~0.25 h
- ExcretionN/A
- Urinary Excretion12
- Clerance14.6 ml/min/kg
- ToxicityNicotinic acid can cause vasodilation of cutaneous blood vessels resulting in increased blood flow, principally in the face, neck and chest. This produces the niacin- or nicotinic acid-flush. The niacin-flush is thought to be mediated via the prostaglandin prostacyclin.
- LD50 (rat)LD50=7000 mg/kg
- LD50 (mouse)N/A